Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma

Background pStage I includes clinicopathologically diverse groups. This study aimed to identify the prognostic factors for pStage I lung adenocarcinoma. Methods We retrospectively reviewed 208 patients with pStage I adenocarcinomas who underwent curative resection in our institute between 2006 and 2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical oncology 2020-06, Vol.25 (6), p.1079-1089
Hauptverfasser: Kawakita, Naoya, Toba, Hiroaki, Kawakami, Yukikiyo, Takizawa, Hiromitsu, Bando, Yoshimi, Otuska, Hideki, Matsumoto, Daisuke, Takashima, Mika, Tsuboi, Mitsuhiro, Yoshida, Mitsuteru, Kondo, Kazuya, Tangoku, Akira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background pStage I includes clinicopathologically diverse groups. This study aimed to identify the prognostic factors for pStage I lung adenocarcinoma. Methods We retrospectively reviewed 208 patients with pStage I adenocarcinomas who underwent curative resection in our institute between 2006 and 2013. The maximum standardized uptake value (SUVmax) on [F18]-fluoro-deoxy- d -glucose positron emission tomography-computed tomography (PET/CT) was evaluated. Adenocarcinomas were categorized into the following histologic groups: group 0 (minimally invasive adenocarcinoma and lepidic predominant adenocarcinoma), group 1 (papillary predominant adenocarcinoma), and group 2 (acinar predominant adenocarcinoma and all the remaining subtypes). We assessed the relationship between disease-free survival (DFS) and clinicopathological factors. Results Multivariate analysis of DFS demonstrated that SUVmax > 3.0 ( p   20 mm ( p  = 0.016), and histologic groups ( p   3.0: 2 points) + total tumor size (≤ 20 mm: 0 point, > 20 mm: 1 point) + histologic group (group 0: 0 point, group 1: 1 point, group 2: 2 points). Patients were divided into the following three risk groups: low-risk (PRS 0–2 points, n  = 136), intermediate-risk (PRS 3–4 points, n  = 49), and high-risk groups (PRS 5 points, n  = 13). The 5-year DFS rates were 93.2%, 50.6%, and 30.8% for the low-, intermediate-, and high-risk groups, respectively ( p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-020-01637-6